Managing Sarcopenia and Its Related-Fractures to Improve Quality of Life in Geriatric Populations

Tetsuro Hida¹*, Atsushi Harada², Shiro Imagama¹, Naoki Ishiguro¹

¹Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine
²Department of Orthopedic Surgery, National Center for Geriatrics and Gerontology

[Received October 10, 2013; Revised November 19, 2013; Accepted November 24, 2013]

ABSTRACT: Sarcopenia, an aging-induced generalized decrease in muscle mass, strength, and function, is known to affect elderly individuals by decreasing mobile function and increasing frailty and imbalance that lead to falls and fragile fractures. Sarcopenia is a known risk factor for osteoporotic fractures, infections, and early death in some specific situations. The number of patients with sarcopenia is estimated to increase to 500 million people in the year 2050. Sarcopenia is believed to be caused by multiple factors such as disuse, malnutrition, age-related cellular changes, apoptosis, and genetic predisposition; however, this remains to be determined. Various methods have been developed, but no safe or effective treatment has been found to date. This paper is a review on the association between sarcopenia and its related-fractures and their diagnoses and management methods to prevent fractures.

Key words: sarcopenia, sarcopenia-related fracture, osteoporosis, diagnosis, muscle mass, treatment, pathogenesis

Sarcopenia, an aging-induced decrease in muscle mass, is known to affect elderly individuals by decreasing activities of daily living and increasing frailty and vulnerability to falls and osteoporotic fractures.

In the field of orthopedics, the elements of the musculoskeletal system have been classified as follows: the “muscles,” the source of the power; the “tendons,” which bind the muscles and the bones; the “bones,” which are load-bearing structures; and the “joints,” which connect bones with other bones. Thus far, efforts have been made to deepen the understanding of the functions and impairments of each of those elements. Compared with other musculoskeletal disorders such as fractures, osteoarthritis, and tendon or ligament ruptures, muscles have a high capacity to regenerate and are often believed to “heal even without treatment.” [1] Unfortunately, there has been a delay in the understanding of the pathophysiology of muscular regeneration and sarcopenia as well as the awareness of treatments. In fact, the regenerative capacity of skeletal muscles is decreased in the elderly; in recent years, it has been found that even when the muscles regenerate, the muscle fibers are abnormal, fatty, and fibrosed [2-4] in aged environment. Such a decrease in muscle mass and strength causes a physical instability that makes the body fall easily, resulting in reduced mobility [5]; and ultimately, the patient experiences falls and fractures and is confined to bed [6, 7].

Sarcopenia has been reported to affect more than 40% of elderly individuals ≥70 years of age, approximately 50 million people worldwide. This number is estimated to increase to 500 million people in the year 2050 [8]. Therefore, there has been major interest in developing strategies to reduce the disadvantage of sarcopenia and help in attenuating the age related decline and disability. In this communication, we comment on the association between sarcopenia and osteoporotic fractures, and the management of sarcopenia to prevent osteoporotic fractures.
Definition and Diagnosis of Sarcopenia

The term sarcopenia is a recently coined term, which originates from the Greek words sarx, meaning muscle, and penia, meaning loss. It was first demonstrated by Rosenberg [9] in 1989. Recently, the European Working Group on Sarcopenia in Older People (EWGSOP) published a useful guideline [8] in 2010. A similar guideline was published by the International Working Group on Sarcopenia (IWGS)[10]. In these guidelines, sarcopenia is defined as a progressive and generalized loss of muscle mass and low muscle function (strength or performance). Classification of sarcopenia by cause is also suggested in this guideline. ‘Primary’ sarcopenia is defined as when no other cause is evident but ageing itself. Sarcopenia can be considered ‘secondary’ when one or more other causes are evident. Because this classification is preliminary one, the study comparing each type of sarcopenia does not exist, so the evidence for specific treatment for primary or secondary was not established yet. Figure 1 shows the algorithm of diagnosing sarcopenia by EWGSOP. The cutoff values for grip strength and habitual gait speed (less than 0.8 m/s) have been used to assess muscle strength and performance loss. On the other hand, the IWGS guideline established a cutoff value for gait speed (less than 1.0 m/s) only. However, not only muscle mass loss but also muscle strength or performance loss is mandatory to diagnose sarcopenia.

Figure 1. Recommended algorithm for diagnosing sarcopenia from EWGSOP (ref.8, partly modified from original)

Measuring techniques for muscle mass

In general, maximum muscle mass is observed between the ages of 20 and 30 years in men and women, and muscle mass gradually decreases with age [11-14]. After the age of 45 years, 0.3% of muscle mass is lost from the total body weight annually [15]. Three major methods are used for evaluating muscle volume, namely (1) analysis of cross-sectional area (CSA) by magnetic resonance imaging or computed tomographic (CT) scanning, (2) dual-energy X-ray absorptiometry (DXA), and (3) bioelectrical impedance analysis (BIA).
(1) Cross-sectional area

CSA directly reflects the muscle mass of a specific part of the body, and is considered one of the most accurate measuring methods. The midthigh muscle is the most preferred part for CSA measurement; it is highly associated with lower extremity function [2, 16-20]. Greater psoas muscle, lumbar paraspinal muscles, and rectus abdominis muscle are also often used because they can be evaluated simultaneously through abdominal examination by CT scan; thus, they are mainly used for evaluating sarcopenia in patients with gastrointestinal disease[21-23]. However, the use of the CSA has some limitations. For diagnosing sarcopenia, the cutoff value from the normal young mean has not been established yet. Other demerits for CSA are less accessibility, high cost, and radiation exposure (CT scan). CSA is the criterion standard for research use, but more noninvasive alternatives such as DXA or BIA are more preferred for clinical use.

(2) Dual-energy X-ray absorptiometry

DXA is a traditional method for determining body composition, which is classically used for measuring bone mineral density[24]. Two X-ray beams of different energy levels are aimed at the patient’s body. Body compositions such as bone mass, fat mass, and lean soft tissue mass were determined from the absorption rate of each X-ray beam. Whole-body DXA can independently estimate the composition of each part of the body. Its exposure dose of radiation is quite low compared with X-ray examination or CT scan[25]. The lean masses of the head and trunk contain not only muscle but also the brain and internal organs, respectively. In contrast, the arms and legs contain only skeletal muscle. The skin and vessels are so minimal that they can be ignored. We can measure skeletal muscle mass with accuracy at the arms and legs[26]. For this reason, appendicular muscle mass (ASM) is preferred for evaluating sarcopenia by DXA [5, 27]. DXA has adequate precision and reproducibility compared with CSA[17]. Technical errors in DXA for CSA by CT scan are reported in only 2.5% of cases[25]. DXA is currently a preferred method for research and clinical use.

(3) Bioelectrical impedance analysis

BIA also is a noninvasive and traditional method for measuring body composition [28, 29]. Electrodes are attached to various parts of the body, and a small electric signal is circulated. BIA measures the impedance or resistance of muscle and fat tissues and estimates tissue content and composition. Modern BIA can separately measure each part of the body. The best feature of BIA is the portability of the equipment used, making it suitable for epidemiological examination for community-dwelling people [30, 31]. The validity of BIA, however, is not ascertained for the population whose hydration status alters with edematous disease[15], such as heart failure, renal failure, and lymphedema. BIA is regarded as an accurate alternative for epidemiological and clinical uses [32-34].

Some other noninvasive methods have been developed. In particular, ultrasonography can investigate muscle thickness (muscle volume) [35] and muscle echo intensity (muscle quality) [36-39] at one time. Ultrasonography is a potentially useful method for evaluating sarcopenia. Anthropometric measurements such as calf circumference are traditional and convenient methods of measuring skeletal muscle mass, although they are easily influenced by subcutaneous fat and their reliability is inadequate for sarcopenia screening [40].

The cutoff value for sarcopenia was established by Baumgartner in 1998. He proposed the use ASM from DXA examination relative to height. Individuals with ASM/height², which is the sum of arm and leg muscle masses divided by the square of height, of two standard deviations below the mean of young healthy volunteers were considered as likely to have sarcopenia [11]. The expression ASM/height² is synonymous to appendicular lean mass/height² (often abbreviated to “aLM/h²”) [41] and skeletal muscle mass index (often abbreviated to “SMI”) [42, 43]. The cutoff value for BIA is similar to that for DXA[32, 33].

Sarcopenia and its related fractures

Sarcopenia-induced functional impairment and frailty

The decrease in muscle mass in the elderly has two aspects. The first aspect is a decrease in muscle mass as part of the musculoskeletal system. Sarcopenia should be taken into consideration as the cause of “locomotive syndrome”, which is defined by the Japanese Orthopedic Association (JOA) as a condition in people with musculoskeletal disease in high-risk groups who are highly likely to require nursing care at some point [44-49], as well as “musculoskeletal ambulation disability symptom complex,” condition in which aging causes a reduced capacity to maintain balance and a decrease in mobility and walking ability [50]. For example, an 80 year-old female who was injured at home and developed a hip fracture (Figure 2) had a standing height of 149 cm, a body weight of 32 kg, and an ASM/height² of 4.8 kg/m², and the fracture was diagnosed as a complication of sarcopenia. After surgery, the patient was capable of walking with support and was discharged from the hospital to a nursing home [51]. It is easily imaginable that...
the risk of osteoporotic fracture is higher in elderly individuals with sarcopenia.

**Muscle mass and bone density**

Reports have shown that sarcopenia is associated with decreased bone density. In a study conducted on 352 elderly individuals, Coin et al reported a positive correlation between bone density and muscle mass [73]. In a survey conducted on 600 patients aged 45–80 years, Wu et al. reported that sarcopenia was an independent risk factor for osteoporosis [74]. In other words, it can be said that “patients with less muscle mass have a low bone density.” As shown in Figure 3, causes that are common to sarcopenia and osteoporosis, such as disuse, malnutrition, and vitamin D deficiency, lead to simultaneous loss of bone and bone strength with a decrease in muscle mass and a predisposition to falls [75]. These findings suggest that fractures are caused by a combination of osteoporosis and sarcopenia.

**Sarcopenia and osteoporotic fractures**

Osteoporotic fractures are rapidly increasing in incidence worldwide as the population ages [76]. According to a report published by JOA in 2009, approximately 180,000 hip fracture cases occur per year in Japan, and approximately 2 million vertebral fractures are reported per year [77]. According to a report published by the World Health Organization, hip fractures, which had an incidence of approximately 1.5 million cases per year worldwide in 1990, are expected to rise to 2.7 million cases annually in 2025 (World Health Organization. [www.who.int/ageing/en/](http://www.who.int/ageing/en/), accessed 30th, April/2009), and the majority of this increase is predicted to be due to an increase in the elderly population in Asian countries including Japan and China [78]. Osteoporotic fractures cause patients to fall into a bedridden state, severely impacting their ADLs and leading them to require nursing care. In other countries as well, social security costs associated with osteoporosis are increasing steadily [79]. In world wide fragile economic condition, the prevention of osteoporotic fractures through the early detection and treatment of sarcopenia could be an effective prescription for the use of limited social resources [80].

However, there have been only a limited number of reports on the realities pertaining to sarcopenia in patients with osteoporotic fractures [41, 81-83]. In our past study of 327 patients with hip fracture and 2511 outpatient controls, we found a higher prevalence of sarcopenia in patients with hip fractures and the presence of sarcopenia as an independent risk factor for a hip fracture [43].

Thus, sarcopenia is a potential risk factor for osteoporosis and subsequent fracture, and its management is the key to preventing osteoporotic fracture.
Etiology of sarcopenia

The etiology of sarcopenia comprises a wide variety of causes that are involved in a complex manner, including the aforementioned disuse secondary to comorbidities (malnutrition\[84\], vitamin D deficiency \[85\], cerebral infarction, heart failure, and osteoarthritis \[86\], disuse \[6, 87\]) as well as age-related hormonal changes (involving testosterone \[88-90\], estrogen \[91, 92\], insulin-like growth factor I \[93\], and insulin\[94\]), apoptosis \[95\], denervation \[96\], and changes in inflammation and immunity involving interleukin (IL)-1, IL-6 and tumor necrosis factor-α\[97\], social causes, and mental causes such as decline in cognitive function \[98\] or decrease in social activity. It has been reported that in the histological examination of muscle fibers, type II muscle fibers (in other words, the so-called fast muscles) decrease with age, while type I muscle fibers (in other words, the so-called slow muscles) are preserved \[99\]. The decrease in fast muscles causes a delay in the muscle contraction reaction time; as a result, the righting reflex and the protective extension reflex are too late when the body vacillates, which may cause a fall.

Various types of signal transduction systems such as the Akt/mTOR signaling system and the Notch signaling system have recently been found to be involved in the molecular mechanisms of muscle fiber tissue regeneration \[100-102\]. Most of all, the Wnt/β-catenin signaling system is one of the signal transduction pathways involved in muscle regeneration.

Brack et al. reported that the serum of aged mice contained high levels of Wnt, that the substances that activated the Wnt signal in the serum caused abnormal fibrosis in the regenerating muscle, and that they were able to suppress fibrosis in aged mice by administering Dkk1, a Wnt inhibitor \[103\]. Naito et al. reported identifying the complement molecule C1q as a new Wnt signal activator, where the administration of C1q in young mice resulted in a decline in the regenerative capacity, whereas the administration of neutralizing antibodies against C1s resulted in an improvement of the age-related decline in the regenerative capacity \[104\]. The findings
showed that through Wnt signal activation, C1q caused a decline in regenerative capacity after skeletal muscle damage, which is one of the phenotypes of aging.

Interestingly, the Wnt/β-catenin signaling system is also involved in osteoblast differentiation. In rats, inhibition of the Wnt signaling system by using Dkk1 has been found to decrease bone mineral density, while anti-Dkk1 neutralizing antibody has been found to increase bone mineral density [105]. In humans as well, blood levels of DKK1 have been found in be elevated in patients with osteoporosis, although the causality remains unclear [106]. Activation of the Wnt signaling system through sclerostin antibody is viewed as a target in the prevention of osteoporotic fractures and the development of new drugs for the treatment of osteoporosis [107]. However, one should keep in mind that inhibiting Wnt signaling also has some negative aspects, especially with regard to muscle regeneration.

Much remains unknown in the molecular biological mechanism of muscle aging, and further elucidation in this area is desired.

Treating sarcopenia to prevent fractures

Multiple factors are involved in the pathogenesis of sarcopenia; therefore, the development of a specific treatment is quite difficult and evidence of effective treatment is limited. The therapeutic methods that are currently being attempted can be roughly classified as follows: (1) exercise therapy, (2) nutritional therapy, and (3) pharmacological treatment.

(1) Exercise therapy

There has been much evidence to support the fact that the so-called elderly “muscle training” is effective. In randomized controlled trials using high-intensity muscle strength training in 39 postmenopausal women, Nelson et al. reported improved muscle mass, muscle strength, and balance [108]. In a meta-analysis of a total of 1,328 patients in 49 studies consisting of randomized controlled trials on muscle strength training, Peterson et al. concluded that muscle strength training effectively increased muscle mass [109]. However, from the perspective of preventing osteoporotic fractures, performing exercise therapy directly may pose some issues. Patients with osteoporotic fractures often show various complications [110]. In addition to such a deterioration of mental function, patients with a high risk of fragile fracture are also affected by paralysis caused by the original cerebrovascular disease, locomotor disorders caused by osteoarthritis and complications of heart disease; moreover, their locomotor functions are believed to be lower than those of healthy subjects. When clinicians are managing more debilitated elderly patients with lower cognitive function and motor function, some improvement is needed when performing efficient muscle strength training while maintaining treatment compliance. Of course, for highly active elderly patients who are capable of performing exercise therapy by themselves, it can be said that exercise therapy is safe and highly effective for sarcopenia.

(2) Nutritional therapy

A study conducted on 403 institutionalized elderly women in Japan showed a high rate (49.1%) of vitamin D deficiency with serum 25(OH)D3 levels ≤16 ng/mL. Patients with a potential vitamin D insufficiency are believed to be numerous [111]. In addition to the role of vitamin D in increasing the bone mass, vitamin D receptors in striated muscles are also responsible for increasing muscle strength and muscle mass [85, 112]. The ingestion of a sufficient amount of vitamin D as a supplement is known to have a preventive effect against falls and fractures [85, 113-115]. Administration of vitamin D in the elderly may effectively treat sarcopenia and prevent osteoporotic fractures.

Most elderly subjects have insufficient caloric and protein intake, and the combination of exercise and dietary supplements containing amino acids and proteins may have an effect on sarcopenia. A short-term increase in muscle mass and muscle strength results, even in the elderly [109, 116]. Bonnefoy et al. examined the combination of dietary supplements and exercise by using a randomized controlled trial [117]. Dietary intervention based on nutritional supplement drinks containing proteins and exercise therapy was conducted for 9 months in 57 elderly women, and the effects were compared with those of a placebo. Forty-two participants completed the tests and showed improved muscle strength. However, it is important to note that the effect of dietary supplements on preventing osteoporotic fractures has not yet been clarified and that a decrease in adherence to nutritional therapy may occur in addition to reduced intake of regular food.

(3) Pharmacological treatment

Testosterone is a typical and strong anabolic hormone. A clinical trial examining testosterone replacement therapy was discontinued after 6 months due to an increasing number of cardiovascular events [118]. However, a significant increase in muscle strength was found in the testosterone-treated group.

Clenbuterol, which stimulates β2 sympathetic receptors and is used in the treatment of bronchial asthma, causes an increase in skeletal muscles by acting on the
PI3K/Akt signal system [119]. Clenbuterol is known to increase lean meat in pork, and abused by livestock industry in some countries. β stimulant is also a target drug in doping tests, so that athletes were warned not to eat pork in such countries (Telegraph Sport and Agencies. London 2012 Olympics: China bans athletes from eating meat for fear of ingesting banned substance clenbuterol. The Telegraph. United Kingdom: Telegraph Media Group Limited, 2012/03/02). Clenbuterol has previously been reported to cause an increase in muscle mass when administered to patients with heart failure[120]; however, a large-scale case-control study conducted in Denmark on patients using β-stimulants and those with osteoporotic fractures concluded that short-acting β-stimulants were a risk factor for osteoporotic fracture and that other types of β-stimulants had no effect on osteoporotic fractures[121].

Angiotensin-converting-enzyme (ACE) inhibitor, the strong candidates for the treatment of sarcopenia, was originally an anti-hypertensive medication that was used to prevent cardiovascular disease [122] and diabetic nephropathy [123]. ACE inhibitors have been used for a long time and their dosage, administration, and side effects are already known. ACE inhibitor is known to decrease muscle fibrosis in vitro through connective tissue growth factor (CTGF/CCN-2) [124]. Several clinical studies have reported that ACE inhibitor improved exercise performance in patients with heart failure [125-128]. Of course, these studies are biased towards improved heart function, but the direct effect on skeletal muscle tissue cannot be denied.

Other pharmacological therapies, such as growth hormone [129], insulin-like growth factor1 [130], and estrogen [92, 131, 132] have also been attempted, but no clear evidence has yet been found. The methods for increasing muscle mass are the same for young athletes and the elderly. Even in the elderly, muscle mass has been shown to increase upon engaging in muscle strength training (exercise therapy), ingesting proteins (nutritional therapy), and doping (pharmacological treatment). However, the fact that there is a need to continue treatment while maintaining safety and compliance in debilitated elderly subjects suffering from complications makes it difficult to treat sarcopenia.

Conclusion

Awareness of sarcopenia, specifically as a risk factor for falls and fractures in the elderly, is necessary. The treatment of sarcopenia will be an important element in the future prevention of fractures. However, evidence pertaining to the treatment of sarcopenia for the purpose of preventing fragile fractures remains insufficient. To reduce the number of patients suffering from osteoporotic fractures, there is an urgent need to further elucidate the facts about and develop therapeutic methods for sarcopenia.

Conflicts of interest

No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.

References

[1] Kanda K, Sugama K, Hayashida H, Sakuma J, Kawakami Y, Miura S, et al. (2013). Eccentric exercise-induced delayed-onset muscle soreness and changes in markers of muscle damage and inflammation. Exerc Immunol Rev, 19: 72-85
[2] Lang T, Cauley JA, Tylavsky F, Bauer D, Cummings S, Harris TB (2010). Computed tomographic measurements of thigh muscle cross-sectional area and attenuation coefficient predict hip fracture: the health, aging, and body composition study. J Bone Miner Res, 25: 513-519
[3] Akhmetshina A, Palumbo K, Dees C, Bergmann C, Venalis P, Zerr P, et al. (2012). Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis. Nat Commun, 3: 735
[4] Joe AWB, Yi L, Natarajan A, Le Grand F, So L, Wang J, et al. (2010). Muscle injury activates resident fibro/adipogenic progenitors that facilitate myogenesis. Nat Cell Biol, 12: 153-163
[5] Waters DL, Hale L, Grant AM, Herbison P, Goulding A (2010). Osteoporosis and gait and balance disturbances in older sarcopenic obese New Zealanders. Osteoporos Int, 21: 351-357
[6] Berg HE, Larsson L, Tesch PA (1997). Lower limb skeletal muscle function after 6 wk of bed rest. J Appl Physiol, 82: 182-188
[7] Coker RH, Wolfe RR (2012). Bedrest and sarcopenia. Curr Opin Clin Nutr Metab Care, 15: 7
[8] Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. (2010). Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing, 39: 412-423
[9] Rosenberg I (1989). Summary comments. Am J Clin Nutr, 50: 1231-1233
[10] Fielding RA, Vellas B, Evans WJ, Bhasin S, Morley JE, Newman AB, et al. (2011). Sarcopenia: An Undiagnosed Condition in Older Adults. Current Consensus Definition: Prevalence, Etiology, and Consequences. International Working Group on Sarcopenia. J Am Med Dir Assoc, 12: 249-256
[11] Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, et al. (1998). Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol, 147: 755-763
[12] Fantin F, Di Francesco V, Fontana G, Zivelonghi A, Bissoli L, Zoico E, et al. (2007). Longitudinal body composition changes in old men and women:
interrelationships with worsening disability. J Gerontol A Biol Sci Med Sci, 62: 1375-1381

[13] Sanada K, Miyachi M, Tanimoto M, Yamamoto K, Murakami H, Okumura S, et al. (2010). A cross-sectional study of sarcopenia in Japanese men and women: reference values and association with cardiovascular risk factors. Eur J Appl Physiol, 110: 57-65

[14] Baumgartner RN, Waters DL, Gallagher D, Morley JE, Garry PJ (1999). Predictors of skeletal muscle mass in elderly men and women. Mech Ageing Dev, 107: 123-136

[15] Janssen I, Heymsfield SB, Baumgartner RN, Ross R (2000). Estimation of skeletal muscle mass by bioelectrical impedance analysis. J Appl Physiol, 89: 465-471

[16] Delmonico MJ, Harris TB, Visser M, Park SW, Conroy MB, Velasquez-Meyer P, et al. (2009). Longitudinal study of muscle strength, quality, and adipose tissue infiltration. Am J Clin Nutr, 90: 1579-1585

[17] Hansen RD, Williamson DA, Finnegan TP, Lloyd BD, Grady JN, Diamond TH, et al. (2007). Estimation of thigh muscle cross-sectional area by dual-energy X-ray absorptiometry in frail elderly patients. Am J Clin Nutr, 86: 952-958

[18] Kato A, Ishida J, Endo Y, Takita T, Furusashi M, Maruyama Y, et al. (2011). Association of abdominal visceral adiposity and thigh sarcopenia with changes of arteriosclerosis in haemodialysis patients. Nephrol Dial Transplant, 26: 1967-1976

[19] Newman AB, Kupelian V, Visser M, Simonsick EM, Goodpaster BH, Kritchevsky SB, et al. (2006). Strength, but not muscle mass, is associated with mortality in the health, aging and body composition study cohort. J Gerontol A Biol Sci Med Sci, 61: 72-77

[20] Visser M, Kritchevsky SB, Goodpaster BH, Newman AB, Nevitt M, Stumm E, et al. (2002). Leg muscle mass and composition in relation to lower extremity performance in men and women aged 70 to 79: the health, aging and body composition study. J Am Geriatr Soc, 50: 897-904

[21] Harimoto N, Shirabe K, Yamashita YI, Ikegami T, Yoshizumi T, Soejima Y, et al. (2013). Sarcopenia as a predictor of prognosis in patients following hepatectomy for hepatocellular carcinoma. Br J Surg, 100: 1523-1530

[22] Pezaro C, Mukherji D, Tunaru I, Cassidy AM, Omlin A, Bianchini D, et al. (2013). Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer. Br J Cancer, 109: 325-331

[23] Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, et al. (2013). Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol, 31: 1539-1547

[24] Nuti R, Martini G (1992). Measurements of bone mineral density by DXA total body absorptiometry in different skeletal sites in postmenopausal osteoporosis. Bone, 13: 173-178

[25] Wang ZM, Visser M, Ma R, Baumgartner RN, Kotler D, Gallagher D, et al. (1996). Skeletal muscle mass: evaluation of neutron activation and dual-energy X-ray absorptiometry methods. J Appl Physiol, 80: 824-831

[26] Baumgartner RN, Stauber PM, McHugh D, Koehler KM, Garry PJ (1995). Cross-sectional age differences in body composition in persons 60+ years of age. J Gerontol A Biol Sci Med Sci, 50: M307-M316

[27] Kyle Ug, Genton L, Hans D, Karsegard VL, Michel JP, Slosman DO, et al. (2001). Total body mass, fat mass, fat-free mass, and skeletal muscle in older people: cross-sectional differences in 60-year-old persons. J Am Geriatr Soc, 49: 1633-1640

[28] Hoffer EC, Meador CK, Simpson DC (1969). Correlation of whole-body impedance with total body water volume. J Appl Physiol, 27: 531-534

[29] National Institutes of Health (1996). Bioelectrical impedance analysis in body composition measurement: National Institutes of Health Technology Assessment Conference Statement. Am J Clin Nutr, 64: 524S-532S

[30] Roubenoff R, Baumgartner RN, Harris TB, Dallas GE, Hannan MT, Economos CD, et al. (1997). Application of bioelectrical impedance analysis to elderly populations. J Gerontol A Biol Sci Med Sci, 52: M129-M136

[31] Roubenoff R (1996). Applications of bioelectrical impedance analysis for body composition to epidemiologic studies. Am J Clin Nutr, 64: 459S-462S

[32] Chien MY, Huang TY, Wu YT (2008). Prevalence of Sarcopenia Estimated Using a Bioelectrical Impedance Analysis Prediction Equation in Community-Dwelling Elderly People in Taiwan. J Am Geriatr Soc, 56: 1710-1715

[33] Tanimoto Y, Watanabe M, Sun W, Hirota C, Sugiura Y, Kono R, et al. (2012). Association between muscle mass and disability in performing instrumental activities of daily living (IADL) in community-dwelling elderly in Japan. Arch Gerontol Geriatr, 54: e230-e233

[34] Tanimoto Y, Watanabe M, Sun W, Sugiu Y, Tsuda Y, Kimura M, et al. (2012). Association between sarcopenia and higher-level functional capacity in daily living in community-dwelling elderly subjects in Japan. Arch Gerontol Geriatr, 55: e9-e13

[35] Rosenberg JG, Ryan ED, Sobolewski EJ, Scharville MJ, Thompson BJ, King GE (2013). Reliability of panoramic ultrasound imaging to simultaneously examine muscle size and quality of the medial gastrocnemius. Muscle Nerve, Epub ahead of print

[36] Watanabe Y, Yamada Y, Fukimoto Y, Ishihara T, Yokoyama K, Yoshida T, et al. (2013). Echo intensity obtained from ultrasonography images reflecting muscle strength in elderly men. Clin Interv Aging, 8: 993-998

[37] Radaelli R, Bottaro M, Wilkinson EJ, Wagner DR, Pinto RS (2012). Time course of strength and echo intensity recovery after resistance exercise in women. J Strength Cond Res, 26: 2577-2584

[38] Fukumoto Y, Ikezoe T, Yamada Y, Tsukagoshi R, Nakamura M, Noda M, et al. (2012). Skeletal muscle quality assessed from echo intensity is associated with muscle strength of middle-aged and elderly persons. Eur J Appl Physiol, 112: 1519-1525

[39] Cadore EL, Izquierdo M, Conceicao M, Radaelli R, Pinto RS, Baroni BM, et al. (2012). Echo intensity is associated...
with skeletal muscle power and cardiovascular performance in elderly men. Exp Gerontol, 47: 473-478

[40] Rolland Y, Lauwers-Cances V, Cournot M, Nourhashemi F, Reynish W, Riviere D, et al. (2003). Sarcopenia, calf circumference, and physical function of elderly women: a cross-sectional study. J Am Geriatr Soc, 51: 1120-1124

[41] Di Monaco M, Vallero F, Di Monaco R, Tappero R, Cavanna A (2007). Skeletal muscle mass, fat mass, and hip bone mineral density in elderly women with hip fracture. J Bone Miner Metab, 25: 237-242

[42] Janssen I, Heymsfield SB, Ross R (2002). Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. J Am Geriatr Soc, 50: 889-896

[43] Hida T, Ishiguro N, Shimokata H, Sakai Y, Matsui S, Takemura M, et al. (2013). High prevalence of sarcopenia and reduced leg muscle mass in Japanese patients immediately after a hip fracture. Geriatr Gerontol Int, 13: 413-420

[44] Hirano K, Imagama S, Hasegawa Y, Ito Z, Muramoto A, Ishiguro N (2013). The influence of locomotive syndrome on health-related quality of life in a community-living population. Mod Rheumatol, 23: 939-944

[45] Hirano K, Imagama S, Hasegawa Y, Wakah N, Muramoto A, Ishiguro N (2012). Effect of back muscle strength and sagittal spinal imbalance on locomotive syndrome in Japanese men. Orthopedics, 35: e1073-1078

[46] Nakamura K (2011). The concept and treatment of locomotive syndrome: its acceptance and spread in Japan. J Orthop Sci, 16: 489-491

[47] Muramoto A, Imagama S, Ito Z, Hirano K, Ishiguro N, Hasegawa Y (2012). Physical performance tests are useful for evaluating and monitoring the severity of locomotive syndrome. J Orthop Sci, 17: 782-788

[48] Muramoto A, Imagama S, Ito Z, Hirano K, Tauchi R, Ishiguro N, et al. (2013). Threshold values of physical performance tests for locomotive syndrome. J Orthop Sci, 18: 618-626

[49] Hida T, Sakai Y, Harada A, Imagama S, Ishiguro N (2011). The impact of sarcopenia, the muscle decreasing disease, in cervical compressive myelopathy diagnosed by dual energy X-ray absorptiometry. World Spinal Column J, 2: 148

[50] Michikawa T, Nishiwaki Y, Takebayashi T, Toyama Y (2009). One-leg standing test for elderly populations. J Orthop Sci, 14: 675-685

[51] Hida T, Harada A (2013). Fall Risk and Fracture. Diagnosing sarcopenia and sarcopenic leg to prevent fall and fracture: its difficulty and pit falls. Clin Calcium, 23: 707-712

[52] Pfisterer MH, Griffiths DJ, Schaefer W, Resnick NM (2006). The effect of age on lower urinary tract function: a study in women. J Am Geriatr Soc, 54: 405-412

[53] Dutta C, Hadley EC, Lexell J (1997). Sarcopenia and physical performance in old age: overview. Muscle Nerve Suppl, 5: S5-9

[54] Chen HJ, Kuo CS (1989). Relationship between respiratory muscle function and age, sex, and other factors. J Appl Physiol, 66: 943-948

[55] Kim J, Davenport P, Sapienza C (2009). Effect of expiratory muscle strength training on elderly cough function. Arch Gerontol Geriatr, 48: 361-366

[56] Ney DM, Weiss JM, Kind AJ, Robbins J (2009). Senescent swallowing: impact, strategies, and interventions. Nutr Clin Pract, 24: 395-413

[57] Buehring B, Hind J, Fidler E, Krueger D, Binkley N, Robbins J (2013). Tongue Strength Is Associated with Jumping Mechanography Performance and Handgrip Strength but Not with Classic Functional Tests in Older Adults. J Am Geriatr Soc, 61: 418-422

[58] Kuroda Y, Kuroda R (2012). Relationship between thinness and swallowing function in Japanese older adults: implications for sarcopenic dysphagia. J Am Geriatr Soc, 60: 1785-1786

[59] Nogueira, Reis (2013). Swallowing disorders in nursing home residents: how can the problem be explained? Clin Interv Aging, 8: 221-227

[60] Park YH, Han HR, Oh BM, Lee J, Park JA, Yu SJ, et al. (2013). Prevalence and associated factors of dysphagia in nursing home residents. Geriatric Nursing, 34: 212-217

[61] Cosqueric G, Sebag A, Ducolombier C, Thomas C, Piete F, Weill-Engerer S (2006). Sarcopenia is predictive of nosocomial infection in care of the elderly. Br J Nutr, 96: 895-901

[62] Kim TN, Park MS, Yang SJ, Yoo HJ, Kang HJ, Song W, et al. (2010). Prevalence and determinant factors of sarcopenia in patients with type 2 diabetes: the Korean Sarcopenic Obesity Study (KSOS). Diabetes Care, 33: 1497-1499

[63] Levine ME, Crimmins EM (2012). The impact of insulin resistance and inflammation on the association between sarcopenic obesity and physical functioning. Obesity (Silver Spring), 20: 2101-2106

[64] Srikanthan P, Hevener AL, Karlamangla AS (2010). Sarcopenia exacerbates obesity-associated insulin resistance and dysglycemia: findings from the National Health and Nutrition Examination Survey III. PLoS ONE, 5: e10805

[65] Bijlsma AJ, Meskers CG, van Heemst D, Westendorp RG, de Craen AJ, Maier AB (2013). Diagnostic criteria for sarcopenia relate differently to insulin resistance. Age (Dordr), Epub ahead of print

[66] Aubertin-Leheudre M, Lord C, Goulet ED, Khalil A, Dionne IJ (2006). Effect of sarcopenia on cardiovascular disease risk factors in obese postmenopausal women. Obesity (Silver Spring), 14: 2277-2283

[67] Montano–Loza AJ, Meza–Junco J, Prado CMM, Lieffers J, Baracos VE, Bain VG, et al. (2012). Muscle Wasting Is Associated With Mortality in Patients With Cirrhosis. Clinical Gastroenterology and Hepatology, 10: 166-173.e161

[68] Meza-Junco J, Montano-Loza AJ, Baracos VE, Prado CM, Bain VG, Beaumont C, et al. (2013). Sarcopenia as a Prognostic Index of Nutritional Status in Concurrent Cirrhosis and Hepatocellular Carcinoma. J Clin Gastroenterol, Epub ahead of print

[69] Baracos V, Kazemi-Bajestani SM (2013). Clinical outcomes related to muscle mass in humans with cancer
and catabolic illnesses. Int J Biochem Cell Biol, 45: 2302-2308

[70] Kilgour RD, Vignano A, Trutschnigg B, Lucas E, Borod M, Morais JA (2013). Handgrip strength predicts survival and is associated with markers of clinical and functional outcomes in advanced cancer patients. Support Care Cancer: Epub ahead of print

[71] Moisey LL, Mourtzakis M, Cotton BA, Premji T, Heyland DK, Wade CE, et al. (2013). Skeletal muscle predicts ventilator-free days, ICU-free days, and mortality in elderly ICU patients. Crit Care, 17: R206

[72] Landi F, Liporoti R, Fusco D, Mastropaolo S, Quattrococi D, Proia A, et al. (2012). Sarcopenia and Mortality among Older Nursing Home Residents. J Am Med Dir Assoc, 13: 121-126

[73] Coin A, Perissinotto E, Enzi G, Zamboni M, Inelmen EM, Frigo AC, et al. (2008). Predictors of low bone mineral density in the elderly: the role of dietary intake, nutritional status and sarcopenia. Eur J Clin Nutr, 62: 802-809

[74] Wu C-H, Yang KC, Chang HH, Yen JF, Tsai KS, Huang K-C (2013). Sarcopenia is Related to Increased Risk for Low Bone Mineral Density. J Clin Densitom, 16: 98-103

[75] Walsh MC, Hunter GR, Livingstone MB (2006). Sarcopenia in premenopausal and postmenopausal women with osteopenia, osteoporosis and normal bone mineral density. Osteoporos Int, 17: 61-67

[76] Harada A, Mizuno M, Takemura M, Tokuda H, Okuzumi H, Niino N (2001). Hip fracture prevention trial using hip protectors in Japanese nursing residents. Osteoporos Int, 12: 215-221

[77] Harada A, Matsuyma Y, Nakano T, Deguchi M, Kuratsu S, Sueyoshi Y, et al. (2010). Nationwide survey of current medical practices for hospitalized elderly with spine fractures in Japan. J Orthop Sci, 15: 79-85

[78] Johnell O, Kanis JA (2006). An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int, 17: 1726-1733

[79] Dolan P, Torgerson D (1998). The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporos Int, 8: 611-617

[80] Visser M, Kiel DP, Langlois J, Hannan MT, Felson DT, Wilson PW, et al. (1998). Muscle mass and fat mass in relation to bone mineral density in very old men and women: the Framingham Heart Study. Appl Radiat Isot, 49: 745-747

[81] Capozza RF, Cure-Cure C, Cointry GR, Meta M, Cure P, Rittweger J, et al. (2008). Association between low lean body mass and osteoporotic fractures after menopause. Menopause, 15: 905-913

[82] Di Monaco M, Vallerio F, Di Monaco R, Tappero R (2011). Prevalence of sarcopenia and its association with osteoporosis in 313 older women following a hip fracture. Arch Gerontol Geriatr, 52: 71-74

[83] Hida T, Ishiguro N, Sakai Y, Ito K, Harada A (2012). Sarcopenia as a Potential Risk Factor for Osteoporotic Vertebral Compression Fracture in Japanese Elderly Individuals. J Spine Res, 3: 357

[84] Vanitallie TB (2003). Frailty in the elderly: contributions of sarcopenia and visceral protein depletion. Metabolism, 52: 22-26

[85] Barr R, Macdonald H, Stewart A, Mcguigan F, Rogers A, Eastell R, et al. (2010). Association between vitamin D receptor gene polymorphisms, falls, balance and muscle power: results from two independent studies (APOSS and OPUS). Osteoporos Int, 21: 457-466

[86] Evans WJ (2010). Skeletal muscle loss: cachexia, sarcopenia, and inactivity. Am J Clin Nutr, 91: 1123S-1127S

[87] Covinsky KE, Pierluissi E, Johnston CB (2011). Hospitalization-associated disability. JAMA, 306: 1782-1793

[88] Yuki A, Otsuka R, Kozakai R, Kitamura I, Okura T, Ando F, et al. (2013). Relationship between Low Free Testosterone Levels and Loss of Muscle Mass. Sci Rep, 3: 1818

[89] Sipila S, Narici M, Kjaer M, Pollanen E, Atkinson RA, Hansen M, et al. (2013). Sex hormones and skeletal muscle weakness. Biogerontology, 14: 231-245

[90] Hwang AC, Liu JK, Lee WJ, Lin MH, Peng LN, Won CW, et al. (2013). Association of Androgen with Skeletal Muscle Mass and Muscle Function among Men and Women Age 50 Years and Older in Taiwan: Results from I-Lan Longitudinal Aging Study. Rejuvenation Res, Epub ahead of print

[91] Messier V, Rabasa-Lhoret R, Barbat-Artigas S, Elisha B, Karelis AD, Aubertin-Leheudre M (2011). Menopause and sarcopenia: A potential role for sex hormones. Maturitas, 68: 331-336

[92] Sorensen MB, Rosenfalck AM, Hojgaard L, Ottesen B (2001). Obesity and sarcopenia after menopause are reversed by sex hormone replacement therapy. Obes Res, 9: 622-626

[93] Roubenoff R, Parise H, Payette HA, Abad LW, D’Agostino R, Jacques PF, et al. (2003). Cytokines, insulin-like growth factor 1, sarcopenia, and mortality in very old community-dwelling men and women: the Framingham Heart Study. Am J Med, 115: 429-435

[94] Zoico E, Corzato F, Bambace C, Rossi AP, Micciolo R, Civiero P, et al. (2013). Proinflammatory Cytokines, Myosteatosis and myofibrosis: Relationship with aging, inflammation and insulin resistance. Arch Gerontol Geriatr, 57: 411-416

[95] Armand AS, Laziz I, Djeghloul D, Lecolle S, Bertrand F, et al. (2011). Apoptosis-inducing factor regulates skeletal muscle progenitor cell number and muscle phenotype. PLoS ONE, 6: e27283

[96] Leeuwenburgh C (2003). Role of apoptosis in sarcopenia. J Gerontol A Biol Sci Med Sci, 58: 999-1001

[97] Michaud M, Balardy L, Moulis G, Gaudin C, Peyrot C, Vellas B, et al. (2013). Prolinflammatory Cytokines, Aging, and Age-Related Diseases. J Am Med Dir Assoc, Epub ahead of print

[98] Nourhashemi F, Andreieu S, Gillette-Guyonnet S, Reynish E, Albarede JL, Grandjean H, et al. (2002). Is there a relationship between fat-free soft tissue mass and low cognitive function? Results from a study of 7,105 women. J Am Geriatr Soc, 50: 1796-1801
[99] Larsson L, Sjodin B, Karlsson J (1978). Histochemical and biochemical changes in human skeletal muscle with age in sedentary males, age 22–65 years. Acta Physiol Scand, 103: 31-39

[100] Bodine SC, Stitt TN, Gonzalez M, Kline WO, Stover GL, Bauerlein R, et al. (2001). Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol, 3: 1014-1019

[101] Conboy IM (2003). Notch-Mediated Restoration of Regenerative Potential to Aged Muscle. Science, 302: 1575-1577

[102] Bray SJ (2006). Notch signalling: a simple pathway becomes complex. Nature Reviews Molecular Cell Biology, 7: 678-689

[103] Brack AS, Conboy MJ, Roy S, Lee M, Kuo CJ, Keller C, et al. (2007). Increased Wnt Signaling During Aging Alters Muscle Stem Cell Fate and Increases Fibrosis. Science, 317: 807-810

[104] Naito AT, Sumida T, Nomura S, Liu ML, Higo T, Nakagawa A, et al. (2012). Complement C1q Activates Canonical Wnt Signaling and Promotes Aging-Related Phenotypes. Cell, 149: 1298-1313

[105] Zhang W, Drake MT (2011). Potential Role for Therapies Targeting DKK1, LRP5, and Sororitin in the Treatment of Osteoporosis. Current Osteoporosis Reports, 10: 93-100

[106] Butler JS, Murray DW, Hurson CJ, O'Brien J, Doran PP, O'Byrne JM (2011). The role of Dkk1 in bone mass regulation: Correlating serum Dkk1 expression with bone mineral density. Journal of Orthopaedic Research, 29: 414-418

[107] Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, et al. (2009). Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res, 24: 578-588

[108] Nelson ME, Fiatarone MA, Morganti CM, Trice I, Greenberg RA, Evans WJ (1994). Effects of high intensity strength training on multiple risk factors for osteoporotic fractures. A randomized controlled trial. JAMA, 272: 1909-1914

[109] Peterson MD, Sen A, Gordon PM (2011). Influence of Resistance Exercise on Lean Body Mass in Aging Adults. Med Sci Sports Exerc, 43: 249-258

[110] Russo CR, Ricca M, Ferrucci L (2000). True osteoporosis and frailty-related osteopenia: two different clinical entities. J Am Geriatr Soc, 48: 1738-1739

[111] Terabe Y, Harada A, Tokuda H, Okuzumi H, Nagaya M, Shimokata H (2012). Vitamin D Deficiency in Elderly Women in Nursing Homes: Investigation with Consideration of Decreased Activation Function from the Kidneys. J Am Geriatr Soc, 60: 251-255

[112] Boucher BJ (2012). The problems of vitamin d insufficiency in older people. Aging Dis, 3: 313-329

[113] Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B (2005). Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA, 293: 2257-2264

[114] Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, Staehelin HB, Bazemore MG, Zee KY, et al. (2004). Effect of Vitamin D on falls: a meta-analysis. JAMA, 291: 1999-2006

[115] Bischoff HA, Staehelin HB, Dick W, Akos R, Knecht M, Salis C, et al. (2003). Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial. J Bone Miner Res, 18: 343-351

[116] Kim HK, Suzuki T, Saito K, Yoshida H, Kobayashi H, Kato H, et al. (2012). Effects of Exercise and Amino Acid Supplementation on Body Composition and Physical Function in Community-Dwelling Elderly Japanese Sarcopenic Women: A Randomized Controlled Trial. J Am Geriatr Soc, 60: 16-23

[117] Bonnefoy M, Cornu C, Normand S, Boutitie F, Bugnard F, Rahmani A, et al. (2003). The effects of exercise and protein-energy supplements on body composition and muscle function in frail elderly individuals: a long-term controlled randomised study. Br J Nutr, 89: 731-739

[118] Basaria S, Covilliio AD, Travison TG, Storer TW, Farwell WR, Jette AM, et al. (2010). Adverse events associated with testosterone administration. N Engl J Med, 363: 109-122

[119] Ryall JG, Gregorevic P, Plant DR, Silrence MN, Lynch GS (2002). Beta 2-agonist fenoterol has greater effects on contractile function of rat skeletal muscles than clenbuterol. Am J Physiol Regul Integr Comp Physiol, 283: R1386-1394

[120] Kamalakannan G, Petrilli CM, George I, LaManca J, McLaughlin BT, Shane E, et al. (2008). Clenbuterol Increases Lean Muscle Mass but Not Endurance in Patients With Chronic Heart Failure. The Journal of Heart and Lung Transplantation, 27: 457-461

[121] Vestergaard P (2007). Fracture Risk in Patients With Chronic Lung Diseases Treated With Bronchodilator Drugs and Inhaled and Oral Corticosteroids. Chest, 132: 1599

[122] Lang CC, Struthers AD (2013). Targeting the renin-angiotensin-aldosterone system in heart failure. Nat Rev Cardiol, 10: 125-134

[123] Verbeke F, Lindley E, Van Bortel L, Vanholder R, London G, Cohut P, et al. (2013). A European Renal Best Practice (ERBP) position statement on the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Blood Pressure in Non-dialysis-dependent Chronic Kidney Disease: an endorsement with some caveats for real-life application. Nephrol Dial Transplant, Epub ahead of print

[124] Morales MG, Cabrera D, Cespedes C, Vio CP, Vazquez Y, Brandan E, et al. (2013). Inhibition of the angiotensin-converting enzyme decreases skeletal muscle fibrosis in dystrophic mice by a diminution in the expression and activity of connective tissue growth factor (CTGF/CCN-2). Cell Tissue Res, Epub ahead of print

[125] Sumukadas D, Witham MD, Struthers AD, McMurd MET (2007). Effect of perindopril on physical function in elderly people with functional impairment: a randomized controlled trial. CMAJ, 177: 867-874

[126] Schellenbaum GD, Smith NL, Heckbert SR, Lumley T, Rea TD, Furberg CD, et al. (2005). Weight Loss, Muscle...
Strength, and Angiotensin-Converting Enzyme Inhibitors in Older Adults with Congestive Heart Failure or Hypertension. J Am Geriatr Soc, 53: 1996-2000

[127] Burks TN, Andres-Mateos E, Marx R, Mejias R, Van Erp C, Simmers JL, et al. (2011). Losartan Restores Skeletal Muscle Remodeling and Protects Against Disuse Atrophy in Sarcopenia. Sci Transl Med, 3: 82ra37

[128] Bunout D, Barrera G, de la Maza MP, Leiva L, Backhouse C, Hirsch S (2009). Effects of enalapril or nifedipine on muscle strength or functional capacity in elderly subjects. A double blind trial. J Renin Angiotensin Aldosterone Syst, 10: 77-84

[129] Papadakis MA, Grady D, Black D, Tierney MJ, Gooding G, Schambelan M, et al. (1996). Growth hormone replacement in healthy older men improves body composition but not functional ability. Ann Intern Med, 124: 708

[130] Thompson J, Butterfield G, Gylfadottir U, Yesavage J, Marcus R, Hintz R, et al. (1998). Effects of human growth hormone, insulin-like growth factor I, and diet and exercise on body composition of obese postmenopausal women. J Clin Endocrinol Metab, 83: 1477-1484

[131] Aubertin-Leheudre M, Audet M, Goulet ED, Dionne IJ (2005). HRT provides no additional beneficial effect on sarcopenia in physically active postmenopausal women: a cross-sectional, observational study. Maturitas, 51: 140-145

[132] Kenny AM, Dawson L, Kleppinger A, Iannuzzi-Sucich M, Judge JO (2003). Prevalence of sarcopenia and predictors of skeletal muscle mass in nonobese women who are long-term users of estrogen-replacement therapy. J Gerontol A Biol Sci Med Sci, 58: M436-440